Reply to S. Barni et al, K.R. Dearing et al, and N. Murray

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 483-485

  Paz Ares, Luis G ^a   De Marinis, Filippo ^b   Visseren Grul, Carla ^c   Gridelli, Cesare ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c Eli Lilly and Company   (Netherlands)

^d S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; FEMALE; LUNG TUMOR; MALE; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84897577233     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.6011     Document Type: Letter

References (25)

1. Paz Ares LG, de Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895-2902, 2013
2. Murray N: Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 32:482-483, 2014
3. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
4. Peters S, Adjei AA, Gridelli C, et al: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii56-vii64, 2012 (suppl 7)
5. National Comprehensive Cancer Network: NCCN Guidelines: Non-small cell lung cancer, Version 3.2013. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#nscl
6. Lustberg MB, Edelman MJ: Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 8:38-46, 2007
7. Socinski MA, Stinchcombe TE: Duration of first-line chemotherapy in advanced non-small-cell lung cancer: Less is more in the era of effective subsequent therapies. J Clin Oncol 25:5155-5157, 2007 (Pubitemid 350232245)
8. Soon YY, Stockler MR, Askie LM, et al: Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 27:3277-3283, 2009
9. Scagliotti GV, Gridelli C, de Marinis F, et al: First line chemotherapy with pemetrexed plus cisplatin in advanced nonsquamous non-small cell lung cancer (NSCLC): A comparison of two phase III trials. J Thorac Oncol 6:S1160, 2011 (suppl 2; abstr P3.007)
10. Gridelli C, Paz-Ares L: The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer. Eur J Cancer [epub ahead of print on March 27, 2013]
11. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
12. Scagliotti G, Brodowicz T, Shepherd FA, et al: Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6:64-70, 2011
13. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
14. Belani CP, Wu YL, Chen YM, et al: Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: An exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol 7:567-573, 2012
15. Rodrigues-Pereira J, Kim JH, Magallanes M, et al: A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 6:1907-1914, 2011
16. Bennouna J, Zatloukal P, Krzakowski MJ, et al: Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01-Preliminary results. J Clin Oncol 30:498s, 2012 (suppl; abstr 7575)
17. Grønberg BH, Bremnes RM, Fløtten O, et al: Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-3224, 2009
18. Patel JD, Socinski MA, Garon EB, et al: A randomized, open-label, phase III, superiority study of pemetrexed (Pem) + carboplatin(Cb) + bevacizumab-(Bev) followed by maintenance Pem + Bev versus paclitaxel (Pac) + Cb + Bev followed by maintenance Bev in patients with stage IIIB or IV non-squamous nonsmall cell lung cancer (NS-NSCLC). 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September 6-8, 2012 (abstr LBPL1)
19. Schicher N, Paulitschke V, Alexander Swoboda A, et al: Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 15:3495-3499, 2009
20. Volk LD, Flister MJ, Chihade D: Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 13:327-338, 2011
21. Barlesi F, Scherpereel A, Rittmeyer A, et al: Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004-3011, 2013
22. Barni S, Petrelli F: PARAMOUNT trial: Reopening a window to maintenance therapy. J Clin Oncol 32:480-481, 2014
23. Dearing KR, Weiss GJ: Molecular characterization may be of PARAMOUNT importance. J Clin Oncol 32:481-482, 2014
24. Reck M, Paz-Ares L, de Marinis F, et al: Paramount: Descriptive subgroup analyses of final overall survival (OS) for the phase III study of maintenance pemetrexed (PEM) versus placebo (PLB) following induction treatment with PEM plus cisplatin (CIS) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Ann Oncol 23:ix404 (suppl 9; abstr 1235PD)
25. Chen CY, Chang YL, Shih JY, et al: Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. Lung Cancer 74:132-138, 2011